Risk Factors Update Summary

• Mia Femtech was added to the risk factors, reflecting a shift in the company's focus.
• Accumulated deficit increased from $281 million in 2022 to $360 million in 2023.
• The Company was not a PFIC in 2023, 2022, or 2021, and does not expect to become one.
• Sales of Motiva Implants increased from 95% to 98% of revenues in 2023.
• Revenues are expected to continue being primarily driven by sales of Motiva Implants.
• EU Council removed three jurisdictions from the non-cooperative tax list, including Costa Rica.
• Change management controls were ineffective but have been significantly improved by December 31, 2023.
• Medical training sessions increased from 192 in 2022 to 206 in 2023.
• Construction of the third facility in Costa Rica began in Q3 2021.
• Reforms to Costa Rica's Income Tax Law impact the Company's operations and subsidiaries.
• The remediation of the material weakness in internal controls is expected to be completed in 2024.
• The number of employees decreased from 958 in 2022 to 908 in 2023.
• The material weakness in internal controls identified in 2021 was remediated by December 31, 2023.
• The Board of Directors is transitioning to a declassified structure by 2026.